Immunocore Holdings plc
Immunocore Holdings plc, a pioneering biotechnology company headquartered in Great Britain, is at the forefront of developing innovative T cell receptor (TCR) therapies for cancer and other serious diseases. Founded in 2008, Immunocore has made significant strides in the biopharmaceutical industry, particularly with its proprietary ImmTAC platform, which harnesses the power of T cells to target and destroy cancer cells. With a strong operational presence in Europe and North America, Immunocore has established itself as a leader in the field of immuno-oncology. The company’s flagship product, tebentafusp, has garnered attention for its unique mechanism of action and has received regulatory approvals for treating metastatic uveal melanoma. Recognised for its commitment to advancing cancer treatment, Immunocore continues to push the boundaries of science, positioning itself as a key player in the global biopharmaceutical landscape.
DitchCarbon Score
How does Immunocore Holdings plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Immunocore Holdings plc's score of 22 is lower than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Immunocore Holdings plc's reported carbon emissions
In 2022, Immunocore Holdings plc reported a carbon footprint of approximately 0.0824 kg CO2e per unit of revenue, with total revenue of about USD 174,361,000. For 2023, the company did not disclose specific emissions data but reported a GHG intensity of investee companies at approximately 0.61722 kg CO2e per unit of revenue, with total revenue of about USD 249,428,000. Currently, Immunocore has not set any specific reduction targets or climate pledges, and there are no disclosed emissions for Scope 1, Scope 2, or Scope 3. The company does not inherit emissions data from a parent organization, indicating that its climate commitments and emissions reporting are independent. As the industry increasingly focuses on sustainability, Immunocore's lack of specific targets may be a point of consideration for stakeholders interested in the company's environmental impact and climate strategy.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Immunocore Holdings plc is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
